Compare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ASTRAZENECA PHARMA ALKEM LABORATORIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x - 73.1 - View Chart
P/BV x 6.4 20.6 31.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ASTRAZENECA PHARMA
Mar-18
ALKEM LABORATORIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,278 124.3%   
Low Rs1,232883 139.6%   
Sales per share (Unadj.) Rs417.5228.4 182.8%  
Earnings per share (Unadj.) Rs56.310.4 543.2%  
Cash flow per share (Unadj.) Rs64.716.3 398.0%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.998.8 296.6%  
Shares outstanding (eoy) m119.5725.00 478.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.7 71.4%   
Avg P/E ratio x25.1104.2 24.0%  
P/CF ratio (eoy) x21.866.4 32.8%  
Price / Book Value ratio x4.810.9 44.0%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65327,008 624.5%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m9,1711,535 597.4%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m49,9155,710 874.2%  
Other income Rs m1,645123 1,342.9%   
Total revenues Rs m51,5615,833 884.0%   
Gross profit Rs m8,482463 1,832.4%  
Depreciation Rs m1,006147 682.4%   
Interest Rs m6710-   
Profit before tax Rs m8,451438 1,929.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606179 897.7%   
Profit after tax Rs m6,731259 2,597.9%  
Gross profit margin %17.08.1 209.6%  
Effective tax rate %19.040.8 46.5%   
Net profit margin %13.54.5 297.2%  
BALANCE SHEET DATA
Current assets Rs m27,0623,209 843.3%   
Current liabilities Rs m15,3242,070 740.4%   
Net working cap to sales %23.520.0 117.8%  
Current ratio x1.81.6 113.9%  
Inventory Days Days6772 91.9%  
Debtors Days Days4135 118.2%  
Net fixed assets Rs m12,610790 1,595.5%   
Share capital Rs m23950 478.2%   
"Free" reserves Rs m34,4902,419 1,425.6%   
Net worth Rs m35,0272,469 1,418.5%   
Long term debt Rs m1,2120-   
Total assets Rs m54,3874,605 1,180.9%  
Interest coverage x13.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 74.0%   
Return on assets %13.65.6 241.9%  
Return on equity %19.210.5 183.1%  
Return on capital %24.917.7 140.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563300 2,191.1%   
Fx outflow Rs m3,0122,015 149.5%   
Net fx Rs m3,552-1,715 -207.0%   
CASH FLOW
From Operations Rs m7,25988 8,257.7%  
From Investments Rs m1,864-94 -1,991.7%  
From Financial Activity Rs m-9,273NA-  
Net Cashflow Rs m-150-6 2,631.6%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 15.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 12,856 531.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 19, 2019 11:55 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS